LODO 141
Alternative Names: LODO-141; TIR-199Latest Information Update: 28 Dec 2023
At a glance
- Originator Michigan State University; University of California Riverside School of Medicine
- Developer Ginkgo Bioworks; University of California Riverside School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Renal cell carcinoma; Solid tumours
- No development reported Mantle-cell lymphoma; Multiple myeloma
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Mantle-cell-lymphoma in USA
- 28 Dec 2023 No recent reports of development identified for preclinical development in Multiple-myeloma in USA
- 28 May 2021 Lodo Therapeutics has been acquired and merged into Zymergen